SEC Form 4/A · accession 0001104659-17-022869
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Mark Corrigan
Director
Period of report
Mar 30, 2017
Accepted (ET)
Apr 11, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2,F3 | $10.69 | Mar 30, 2017 | A | 9,600 | A | — | Mar 30, 2027 | Common Shares | 9,600 | 9,600 | D |
Explanation of responses
- F1Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F2This Form 4/A is being filed to correct the exercise price reported in the Form 4 filed on March 31, 2017. The correct exercise price is $10.69.
- F3The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date.